Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophili A patients

Blood

Volumn 121, Issue 6, 2013, Pages 1039-1048

  Whelan, Shawn F J ^a   Hofbauer, Christoph J ^a   Horling, Frank M ^a   Allacher, Peter ^a   Wolfsegger, Martin J ^a   Oldenburg, Johannes ^b   Male, Christoph ^c   Windyga, Jerzy ^d   Tiede, Andreas ^e   Schwarz, Hans Peter ^a   Scheiflinger, Friedrich ^a   Reipert, Birgit M ^a  

^a Baxter Innovation GmbH   (Austria)

^b UNIVERSITY OF BONN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOLUTION; FEMALE; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 84873583409     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-444877     Document Type: Article

References (46)

1. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv Exp Med Biol. 1995;386:35-45.
2. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost. 2004;2(7):1082-1095. (Pubitemid 40186081)
3. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69(5):1475-1480. (Pubitemid 17085310)
4. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood. 2009;114(7): 1423-1428.
5. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95(4):1324-1329. (Pubitemid 30099842)
6. Bray GL, Kroner BL, Arkin S, et al. Loss of highresponder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the multi-center hemophilia cohort study. Am J Hematol. 1993; 42(4):375-379. (Pubitemid 23104809)
7. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381(6585):751-758. (Pubitemid 26243107)
8. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996; 383(6603):787-793. (Pubitemid 26372655)
9. Verbruggen B, van Heerde WL, Laros-van Gorkom BAP. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Haemost. 2009;35(8):752-759.
10. Sahud MA, Pratt KP, Zhukov O, Qu K, Thompson AR. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia. 2007;13(3):317-322. (Pubitemid 46746056)
11. van Helden PMW, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008;142(4):644-652. (Pubitemid 352020215)
12. Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood. 2009;113(11):2587-2594.
13. Lebreton A, Lapalud P, Chambost H, et al. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost. 2011; 105(6):954-961.
14. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348(7):601-608. (Pubitemid 36204954)
15. Suiter TM, Mannucci PM, Kempton CL, et al. Detection of non inhibitory binding antibodies to von Willebrand factor affecting the clearance of VWF:Ag in von Willebrand disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2011; 118(21):987-988.
16. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11(11):792-794.
17. Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J Immunol. 2012;188(8):3628-3638.
18. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82(8):2452-2461. (Pubitemid 23304269)
19. Algiman M, Dietrich G, Nydegger UE, et al. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A. 1992;89(9):3795-3799.
20. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific antiidiotypic antibodies. J Clin Invest. 1994;94(4): 1496-1505. (Pubitemid 24309870)
21. Di Giambattista M, Branckaert T, Hougardy V, Kemball-Cook G, Laub R. In silico prediction of FVIII epitopes recognised by natural autoantibodies inpolyvalent immunoglobulin concentrates. Mol Immunol. 2007;44(8):1903-1913.
22. Djoumerska I, Tcho'banov A, Pashov A, Vassilev T. The autoreactivity of therapeutic intravenous immunoglobulin (IVIg) preparations depends on the fractionation methods used. Scand J Immunol. 2005;61(4):357-363. (Pubitemid 40637841)
23. Bussone G, Dib H, Dimitrov JD, et al. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. Proteomics. 2009;9(8):2253-2262.
24. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006. London, United Kingdom: European Medicines Agency; 2007.
25. Draft Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER); December 2009.
26. Jaki T, Lawo JP, Wolfsegger MJ, et al. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. J Pharm Biomed Anal. 2011;55(5):1148-1156.
27. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267-1281.
28. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
29. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;158(22):209-212.
30. Bonate PL, Sung C, Welch K, Richards S. Conditional modeling of antibody titers using a zeroinflated Poisson random effects model: application to Fabrazyme (R). J Pharmacokin Pharmacodyn. 2009;36(5):443-459.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
32. Zeileis A, Kleiber C, Jackman S. Regression models for count data in R. J Stat Soft. 2008; 27(8):1-25.
33. Zeileis A, Hothorn T. Diagnostic checking in regression relationships. R News. 2002;2(3):7-10.
34. Reding MT, Lei SJ, Lei H, et al. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost. 2002;88(4):568-575. (Pubitemid 35173996)
35. Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988; 334(6179):255-258.
36. Tomer Y, Shoenfeld Y. Ageing and autoantibodies. Autoimmunity. 1988;1(2):141-149.
37. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008;8(6):421-434. (Pubitemid 351733417)
38. Monteiro RC. The role of IgA and IgA Fc receptors as anti-inflammatory agents. J Clin Immunol. 2010;30:S61-S64.
39. Zakarija A, Harris S, Rademaker AW, et al. Alloantibodies to factor VIII in haemophilia. Haemophilia. 2011;17(4):636-640.
40. Vincent AM, Lillicrap D, Boulanger A, et al. Nonneutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. Haemophilia. 2009;15(1):374-376.
41. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39(4):469-477.
42. Satoguina JS, Weyand E, Larbi J, Hoerauf A.T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol. 2005;174(8): 4718-4726. (Pubitemid 40514459)
43. Nirula A, Glaser SM, Kalled SL, Taylora FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23(1):119-124.
44. van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554-1557. (Pubitemid 47417435)
45. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45(6):1538-1546. (Pubitemid 46918338)
46. Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naive and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008;36(2):133-140.